Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study

Bristol-Myers Squibb Company BMY along with Japan’s Ono Pharmaceutical and Bayer AG BAYRY has entered into a collaboration agreement to evaluate the combination of Bristol-Myers’ PD-L1 inhibitor Opdivo (nivolumab) plus Bayer’s Stivarga (regorafenib) for treating patients with microsatellite-stable metastatic colorectal cancer (MSS mCRC), the most common type of CRC.